PRESS RELEASE
News
-
-
-
-
PRESS RELEASE
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025
GENFIT announces positive Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented at EASL Congress 2025 by Ipsen, showing significant efficacy and safety profile improvements -
PRESS RELEASE
GENFIT : les données positives de la Phase 2 évaluant elafibranor dans la Cholangite Sclérosante Primitive (PSC) seront présentées en « late breaking » par Ipsen au congrès de l'EASL 2025
GENFIT annonce les résultats positifs de la Phase 2 sur elafibranor dans la Cholangite Sclérosante Primitive (PSC) à l'EASL 2025 -
-
PRESS RELEASE
GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update
GENFIT reports full-year 2024 financial results and corporate update. Net profit of €1.5 million, Iqirvo® commercial launch in PBC, new ACLF datasets, royalty financing. CEO, Pascal Prigent shares progress and outlook -
-
-
